1 – 23 of 23
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
The prognostic significance of wnt-5a expression in primary breast cancer is extended to premenopausal women.
(
- Contribution to journal › Article
-
Mark
No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression.
(
- Contribution to journal › Article
- 2012
-
Mark
Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer
(
- Contribution to journal › Article
-
Mark
The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER alpha, and is an independent prognostic factor in node-negative breast cancer
(
- Contribution to journal › Article
-
Mark
Med1 plays a critical role in the development of tamoxifen resistance
(
- Contribution to journal › Article
- 2011
-
Mark
Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer.
(
- Contribution to journal › Article
-
Mark
A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen.
(
- Contribution to journal › Article
- 2010
-
Mark
STROMA-DERIVED MARKERS PREDICTING BREAST CANCER PROGNOSIS AND TREATMENT RESPONSE
(
- Contribution to journal › Published meeting abstract
-
Mark
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
(
- Contribution to journal › Article
- 2009
-
Mark
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
2009) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22. p.1564-1574(
- Contribution to journal › Article
-
Mark
Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer.
(
- Contribution to journal › Article
- 2008
-
Mark
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
(
- Contribution to journal › Article
-
Mark
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
(
- Contribution to journal › Article
- 2006
-
Mark
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
(
- Contribution to journal › Article
-
Mark
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance
(
- Contribution to journal › Article
-
Mark
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
(
- Contribution to journal › Article
- 2005
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
(
- Contribution to journal › Article
-
Mark
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
(
- Contribution to journal › Article
-
Mark
Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
(
- Contribution to journal › Article
-
Mark
Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression.
(
- Contribution to journal › Article
-
Mark
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
(
- Contribution to journal › Article
- 2004
-
Mark
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
(
- Contribution to journal › Article